q3-2021 financial performance

Q3-2021 FINANCIAL PERFORMANCE

หน่วย : ลา้นบาทไตรมาส 3/64

(ก.ค.-ก.ย.64)

ไตรมาส 3/63

(ก.ค.-ก.ย.63)เปลี่ยนแปลง+/(-)

9 เดือน ปี 64

(ม.ค.-ก.ย. 64)

9 เดือน ปี 63

(ม.ค.-ก.ย. 63)เปลี่ยนแปลง

รายไดร้วม 244.39 110.58 121.01% 623.54 310.78 100.64%

รายไดจ้ากการขาย 240.38 108.97 120.60% 615.18 306.75 100.55%

กาํไรขั้นตน้ 95.90 65.46 46% 279.10 187.36 49%

EBITDA 36.52 24.55 49% 104.29 66.66 56%

กาํไรสุทธิของกลุ่มบริษทัฯ 25.71 18.46 39% 69.15 49.25 40%

อตัรากาํไรขั้นตน้ (%) 39.9% 60.1% -20.2% 45.4% 61.1% -15.7%

EBITDA margin (%) 14.9% 22.2% -7.3% 16.7% 21.4% -4.7%

อตัรากาํไรสุทธิ (%) 10.5% 16.7% -6.2% 11.1% 15.8% -4.8%

สรุปผลประกอบการสาํคญัในไตรมาสที่ 3 ปี 2564 (งบการเงินรวม)

Revenue from Sales

240.38

108.97

Q32021

Q32020

Revenue from Sales

121

615.18

306.75

9M2021

9M2020

101

Revenue from Sales

97.13 100.65108.97

176.50

198.30

240.38

Q1/20 Q2/20 Q3/20 Q1/21 Q2/21 Q3/21

Revenue for Sales120.60% QoQ100.55% YoY

Unit : Million Baht

Revenue for Sales 9M/21

306.75

615.18

9M/20 9M/21

Gross Profit

95.90

65.46

Q32021

Q32020

46

279.10

187.36

9M2021

9M2020

49

Gross Profit Gross Profit

61.37 60.5365.46

86.46

96.74 95.90

1

Q1/20 Q2/20 Q3/20 Q1/21 Q2/21 Q3/21

Gross profit for 9M

Gross Profit

Gross profit for Q3

46.49% QoQ48.96% YoY

187.36

279.10

9M/20 9M/21

Unit : Million Baht

65.46

95.90

Q3‐63 Q3‐64

187.36

279.10

9M‐63 9M‐64

Gross profit for 9M

Gross Profit

Gross profit for Q3

46.49% QoQ48.96% YoY

Unit : Million Baht

Selling Expenses

36.27

28.22

Q32021

Q32020

29

83.85

9M2021

9M2020

43

Selling Expenses Selling Expenses

120.18

Admin Expenses

28.68

13.43

Q22021

Q22020

39.13

9M2021

9M2020

Admin Expenses Admin Expenses

68.63

114

75

Net Profit

26.41

20.41

Q32021

Q32020

29

72.14

53.75

9M2021

9M2020

34

Net Profit Net Profit

Net Profit 39.30% QoQ

40.40% YoY

ส่วนทเีป็นของบร ิษัทใหญ่

13.87

16.93 18.46 18.68

24.76 25.71

Q1/20 Q2/20 Q3/20 Q1/21 Q2/21 Q3/21

49.25

69.15

9M/20 9M/21

Unit : Million Baht

Net Profit

18.46

25.71

Q3‐63 Q3‐64

49.25

69.15

9M‐63 9M‐64

Unit : MB

39.30% QoQ

40.40% YoY

ส่วนทเีป็นของบร ิษัทใหญ่

Unit : Million Baht

PHARMACEUTICAL INNOVATIONS

Note : 9M‐2021

22.54% 37.58% 1.25% 27.70% 10.93%

Interpharma Group

A company specialized in research & development and distribution of animal’s healthcare products with paid-up registered capital of 5 million Baht

A research & business development company selling pet foodproducts with paid-up registered capital of 4 million Baht

A pharmaceutical company specialized in developing & producing pharmaceutical products for human and animals with paid-up registered capital of 295 million Baht

A research & business development JV company with Thai Union specialized in fish based nutraceuticals with registered capital of 2020 million Baht

55%

60%

100%

51%

100%

Teva Pharma (Thailand) Co., Ltd.Ayutthaya Factory

A pharmaceutical manufacturing plant combining of Silom Medical's diverse product portfolio and contracted manufacturing of Teva Pharma's generics portfolio

A leading nutraceutical company specialized in research & development and distribution of holistic healthcare products with paid-up registered capital of 103 million Baht

Confidential

ORGANIZATION : Board of Director

16

Clinical Professor Emeritus Udom Kachintorn, MD. Independent Director and

Chairman

Professor Dr.Sansanee ChaiyarojIndependent Director

Chairman of the Audit Committee

Mr.Kamtorn Sila-onIndependent Director


Professor Piyamitr Sritara, MD, FRCP, FACP

Independent Director Chairman of the Audit Committee

Independent Directors

Dependent Directors

Trinnawat Thanitiphan Ph.D Miss Napaporn Dechakarat Miss Supaporn RerkpitakpanichDirector and Chief Executive Officer Director and Chief Operation Officer Director and Chief Financial Officer

Confidential

ORGANIZATION : Board of Director

17

Clinical Professor Emeritus Udom Kachintorn, MD. Independent Director and

Chairman

Professor Dr.Sansanee ChaiyarojIndependent Director


Mr.Kamtorn Sila-onIndependent Director

Audit Committee

Dr.Pao SriprasertsukIndependent Director

Audit Committee

Independent Directors

Dependent Directors

Trinnawat Thanitiphan Ph.D Miss Napaporn Dechakarat Miss Supaporn RerkpitakpanichDirector and Chief Executive Officer Director and Chief Operation Officer Director and Chief Financial Officer

Confidential

2021 Company Highlights

7 Growth Engines1. Current 5 business units : New Products /New Channels / New Markets

2. Modern Pharma CMO : Contract Manufacturing Service

3. Interpharma Ayuddhaya Site CMO : Teva

4. Bio Herbal Business : Hemp /CBD, Kratom Projects with Prince Songkhla University, other Thai Herbal Med

5. JV Business : Interpetrina (Asian), Interpharma-ZEAvita,

6. Medical Equipments with PJW

7. New Business Acquisitions : Retail / Wholesales

Business Opportunities : Partnership & Collaboration

Confidential

JV : INTER PETRINA JV : INTERPHARMA ZEAVITA

Business Opportunities : Partnership & Collaboration

Collaboration : 2 MOUs signing with Prince of Songkla University in collaboration to extend research & development on kratom and kratom

extractGovernment Funding : 45 million baht

Collaboration : MOU Signing with RBFon hemp/CBD extract project

Collaboration : MOU signing with PJW on Medical Device from recycled plastics

Confidential

INTERPHARMA TEVA , Feb 9, 2021

lnterpharma\' AL Ue YOUA L i f f ,Ayutthaya Site, Thailand

Area Type Area (Sq. M)Factory 4,932

Production Warehouse

3,5801,352

Utility building 500Maintenance area 100Office building 1,026Canteen 286Stability room 108Car park 1,650Green zone area 7,558Total Used area 16,160

Extendable area 17,280

Total Land Area 33,440

Ayutthaya

Unit : Million Baht

11.07

16.04

‐

2.00

4.00

6.00

8.00

10.00

12.00

14.00

16.00

18.00

Q3‐64 Q4‐64F

Ayutthaya Pharmaceutical

10.45

29.97

‐

5.00

10.00

15.00

20.00

25.00

30.00

35.00

Q3‐64 Q4‐64F

OEM to Teva

JANUARY 7, 2021

PRODUCT PROFILE : COLLAGEN

ใหม่ ซวีติา้ แอคทฟี คอลลาเจน พลสั …แบบซอง

แอคทฟี-ไดเปปไทด ์100%ดูดซมึไดม้ากกว่า 70 เท่า

ใหม่…ซวีติา้ ทูน่าโบนแคลเซยีม พลสั

ผงกระดูกทูน่าธรรมชาต ิ100%เขม้ขน้ 17 เท่า ในเม็ดเล็ก กลนื

ง่าย

PRODUCT PROFILE : CALCIUM

MEDICAL LINEMEDICAL LINE

Modern Pharma : ContractManufacturing Products

Confidential

INTERPHARMA X HUAWEI, FEB 16, 2021

INTERPHARMA Launch Probiota BLMAR 17, 2021

• โปรไบโอตกิ - Bifidobacterium animalis ssp. lactis,

จลุนิทรยีท์อ้งถิน่ ทีม่ตี ัง้แตเ่ด็กแรกเกดิ

• พรไีบโอตกิ – อนิูลนิ (Inulin) อาหารของจลุนิทรยีท์อ้งถิน่

ชนิดดใีนลาํไส ้

“ 2 Power synergistic”

Bifidobacterium animalis ssp. Lactis

Min 5 x10 9 cfuInulin 900 mg

Probiota BL: โพรไบโอตา้ บีแอล

การศึกษา TS6 สูตรผิว เร ืองการ “ฝ้า”

ทาน TS6 สูตรผิว ฝ้าดขี ึนภายใน 3 เดอืน

ศกึษาในผูห้ญิงไทย

อาย ุ 30 – 50 ปีจาํนวน 57 คนทานTS6 วนัละ 1 ซองระยะเวลานาน 3 เดือน

• คอลลาเจนสูตรพเิศษ

• 7 โปรไบโอตกิ + 2 พร ีไบโอตกิ• ละลายงา่ย ดดูซมึเข ้าสู่ร ่างกายได้ด ี

• ไม่มกีลินคาว

• รสราสเบอรร์ ี

Herbal Medicine Application, Jan 29, 2021

HEMP Products

บร ิษัท ดรัก แคร ์จาํกัด

Drugcare Company LimitedProprietary & ConfidentialLive Healthy


Vision


Reliability - fully operate according to Law and

FDA regulations

Pharmacist on duty all day with full range of medicines to serve

Various Product Assortment

Professional service

Premium store image and design

Easy accessible channels(Visible store and Online platform)

VAT REFUND,ALIPAY and WeChat for tourists

Why LAB Pharmacy?

Product Category


General&Chronic Disease

Dermo Cosmetics

Vitamin & Supplement

Personal Care Sport Nutrition

Products for TouristsOrganic & Natural Products

OTC & Medical Healthcare

Food Snack & Beverage

LAB Pharmacy Store


Online Communications


Online Channel

q3-2021 financial performance

Documents